First Interstate Bank Sells 210 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

First Interstate Bank cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,323 shares of the medical research company’s stock after selling 210 shares during the quarter. First Interstate Bank’s holdings in Thermo Fisher Scientific were worth $1,233,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in TMO. Coppell Advisory Solutions LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $36,000. Tyler Stone Wealth Management bought a new position in Thermo Fisher Scientific during the second quarter valued at about $37,000. DHJJ Financial Advisors Ltd. acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth $38,000. Finally, Raleigh Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.6 %

TMO stock traded down $3.22 during trading hours on Tuesday, reaching $554.65. 1,010,297 shares of the stock were exchanged, compared to its average volume of 1,539,256. The firm’s 50-day moving average is $571.79 and its 200-day moving average is $526.53. The company has a market cap of $211.72 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 2.38 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period last year, the firm earned $5.40 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.